In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alpine Immune Sciences Inc. (NASDAQ:ALPN) reported that Biotechnology Value Fund L P has picked up 277,314 of common stock as of 2017-07-27.
The acquisition brings the aggregate amount owned by Biotechnology Value Fund L P to a total of 277,314 representing a 2.0% in the company.
For those not familiar with the company, Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., incorporated on March 30, 2007, is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.
A glance at Alpine Immune Sciences Inc. (NASDAQ:ALPN)’s key stats reveals a current market capitalization of 147.78M based on 15.66M shares outstanding and a price at last close of $9.60 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2017-06-20, Bvf picked up 1,715 at a purchase price of $2.25.This brings their total holding to 201,811 as of the date of the filing.
On the sell side, the most recent transaction saw Rodman unload 6,687 shares at a sale price of $2.27. This brings their total holding to 11,368.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alpine Immune Sciences Inc. (NASDAQ:ALPN) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.